Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond

Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for treatment options in second-line and beyond for your patients with advanced renal cell carcinoma.
Brian A. Costello, MD, MS
Elizabeth R. Plimack, MD, MS
Martin H. Voss, MD
Released: September 8, 2020

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:

  • Treatment sequencing with IO and TKI therapies
  • Optimizing dose for patients with preexisting toxicities
  • Considerations for local control of metastatic sites
  • Ongoing clinical trials

Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.

Link to full program: https://www.clinicaloptions.com/oncology/programs/rcc-immuno-oncology

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

NCCN Logo
Supported by educational grants from
Eisai
Pfizer and EMD Serono

Supported by a medical education grant from
Exelixis, Inc.
Supported by an independent educational grant from
Merck & Co., Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH
Program Director
Yelena Y. Janjigian, MD Sandip P. Patel, MD
Released: June 8, 2022

Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 5, 2022

Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).

Katy E. Beckermann, MD, PhD Released: June 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings